Novocure
- Partner Level
- Gold
- Company Headquarters
- 195 Commerce Way - Portsmouth, NH 03801
- Contact Name
- generalinfo@novocure.com
- Website
- Visit Site
Novocure is an oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized product, Optune® – the TTFields delivery system for glioblastoma (GBM) – was launched in the U.S. for the treatment of recurrent GBM in 2011. In October 2015, Optune became the first FDA-approved therapy in more than a decade for adult patients with newly diagnosed GBM in combination with temozolomide (TMZ). The approval was based on the phase 3 pivotal EF-14 trial which compared Optune plus TMZ vs TMZ alone in newly diagnosed GBM patients.
The science of TTFields has the potential to extend beyond GBM. Novocure has ongoing or completed clinical trials investigating TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.
For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure. For more information about Optune, please visit https://www.optune.com/
